Renal failure therapeutic - Institute of Materia Medica
Latest Information Update: 02 Jun 2016
At a glance
- Originator Institute of Materia Medica
- Class Coumarins
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Renal failure
Most Recent Events
- 02 Jun 2016 Phase-I clinical trials in Renal failure in China (unspecified route) before June 2016